ACTRN12609000981224已完成2 期
The effect of transdermal testosterone gel300mcg daily on cognitive performance in older postmenopausal women: a placebo controlled trial over 26 weeks
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 55 Years 至 65 Years（—）
- 性别
- Female
入选标准
- •1. who are aged 55 to 65 years and have not used systemic oestrogen, testosterone, tibolone or dehydroepiandrosterone(DHEA) therapy for at least 12 months.
- •2. who are at least 12 months postmenopausal. Postmenopausal status will be defined as surgical menopause, natural menopause and >12months of amenorrhea. Hysterectomised women with intact ovaries will be classified as postmenopausal if 58 years and over and if <58 years will require a follicle stimulating hormone (FSH) level > 20IU/L.
- •3. who have evidence of a Pap smear and mammographic screening in the past 24 months with no changes of concern.
- •4. who have provided informed consent by signing the International Regulatory Board (IRB)-approved consent agreement.
排除标准
- •1. Women with any of the following:
- •(a)history of allergic reactions to androgens (oral or patch), topical alcohol, or any component of the formulation
- •(b)any clinically significant skin abnormalities in the area of study drug application (Skin Irritation Scale must < 1 at Visit 2).
- •(c)hot flushes and/or night sweats for which the potential participant wants treatment
- •(d)Sex Hormone Binding Globulin (SHBG) level < 12nmol/L
- •(e)undiagnosed genital bleeding
- •(f)Body Mass Index (BMI) <18 or > 40kg/m2
- •(g)found on the screening to have a Center for Epidemiological Studies Depression Scale (CES-D) score =16.
- •(h)any mammogram results in the past 24 months with pre-cancerous or cancerous findings or any finding that requires follow up in the next 12 months.
- •(i)any abnormal Pap Smear results in the past last 24 months
- •(j)have received anti-androgen therapy or topical minoxidil for alopecia within the last 5 years.
- •(k)have taken any systemic estrogen, including vaginal conjugated equine estrogen, or estrogen progestin therapy within 12 months prior to screening. (Current use of non-systemic vaginal estrogen or phytoestrogens is acceptable.)
- •(l)have received oral, topical, vaginal or patch, implantable or injectable androgen therapy within 12 months prior to screening
- •(m)have used within the 12 weeks prior to screening any of the following medications/preparations that may interfere with the study purpose: systemic corticosteroids (acute use for fewer than 7 days is accepted) or Selective Estrogen Receptor Modulators (SERMs), including tamoxifen.
- •(n)a known severe psychiatric illness.
- •(o)current use of an anti-depressant therapy or antidepressant treatment within the last 3 months
- •(p)neurological disorder that would affect cognition, including history of significant head injury with loss of consciousness, epilepsy, cerebral tumor, stroke and previous intracranial surgery of any kind, Parkinson’s disease, multiple sclerosis.
- •(q)intellectual disability
- •(r)uncontrolled hypertension, Systolic blood pressure (BP) > 160 and/or Diastolic BP > 90
- •(s)a history of cancer except for treated superficial basal cell carcinoma and squamous cell carcinoma of the skin.
- •(t)any history of deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis
- •(u)any serious endocrine disorder with systemic disease. Women with a history of thyroid disease should provide evidence that they are currently euthyroid.
- •(v)known acute or chronic liver disease (bilirubin > x2 the upper limit of normal (ULN), and/or alanine transferase > x3 ULN, aspartate aminotransferase AST> x3 ULN, and/or alkaline phosphatase > x3 ULN
- •(w)insulin dependent diabetes mellitus, acute / chronic renal, liver, cardiovascular disease or any other chronic major illness which would impair overall health and wellbeing
- •2. Women who, in the opinion of the investigator, are a poor medical or psychiatric risk for treatment in a research protocol.
- •3. Women who have participated in a medical or surgical research protocol in the preceding 28 days.
研究者
相似试验
已完成
4 期
The effects of testosterone gel administration in ARTinfertility.Female infertility associated with anovulationIRCT201505197513N11Isfahan University of Medical Sciences64
已完成
4 期
The efficacy of testosterone gel application for increases the sperm concentration in infertile men with oligospermia and low serum testosterone levelTCTR20161030001Faculty of Medicine, Siriraj Hospital16
已完成
2 期
The effect of transdermal testosterone patch (Intrinsa registered trademark) on cognitive performance in older postmenopausal women: a randomized placebo controlled trial over 26 weeks.cognitionMental Health - Studies of normal psychology, cognitive function and behaviourACTRN12610000029099Monash University120
已完成
不适用
Effect of transdermal testosterone replacement in hypogonadal men with decreased insulin sensitivityHypogonadal men with decreased insulin sensitivityNutritional, Metabolic, EndocrineTesticular hypofunctionISRCTN45741714ProStrakan Pharmaceuticals (UK)320
招募中
4 期
Investigating the effect of topical testosterone cream on bone loss and sexual function in women with premature ovarian insufficiency and early menopause: a randomized, double blind, placebo-controlled trial..Primary Ovarian InsufficiencyEarly menopauseMusculoskeletal - OsteoporosisReproductive Health and Childbirth - Other reproductive health and childbirth disordersReproductive Health and Childbirth - Menstruation and menopauseOsteoporosisSexual dysfunctionACTRN12621001100886Monash University116